Drug Profile
MDX 1203
Alternative Names: MDX-1203Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medarex
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Alkylating agents; CD70 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Renal cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in USA (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Renal-cancer in USA (IV, Infusion)
- 30 Nov 2012 Bristol-Myers Squibb completes a phase I trial in Non-Hodgkin's lymphoma and Renal cancer in USA (NCT00944905)